LEO Pharma received marketing authorization (M.A.) from the European Commission for Picato gel. The gel is used to treat adult patients with nonhyperkeratotic, nonhypertrophic actinic keratosis (AK).
The drug comes in two strengths.
Actinic keratosis are small, rough, and raised lesions on the skin that sometimes turn into melanoma, depending on the type of actinic keratosis. These AK lesions develop on areas of the skin that have been exposed to the sun for too long.
The United States approved Pecato gel in January. Australia and Brazil have also given approval.